ABG
VERV

Ally Bridge Group’s Verve Therapeutics VERV Stock Holding History

Ally Bridge Group’s Portfolio VERV Stock Details VERV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-105,360
Closed -$2.4M – 26
2022
Q1 		$2.4M Sell
105,360
-5,000
-5% -$143K 1.78% 21
2021
Q4 		$4.07M Buy
110,360
+95,360
+636% +$4.01M 1.42% 28
2021
Q3 		$705K Buy
+15,000
New +$882K 0.21% 31

Other funds holding VERV

AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Ally Bridge Group's VERV Position: Q2 2022 in Review

Ally Bridge Group sold out of Verve Therapeutics (VERV) in Q2 2022, closing a stake of 105,360 shares — an estimated $2.4M sold.

Ally Bridge Group first reported a position in VERV in Q3 2021 and held it in 3 quarters. The position peaked at $4.07M in Q4 2021. 101 funds tracked by Wall St. Rank hold VERV as of Q2 2022.

  • Ally Bridge Group reported no remaining Verve Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Ally Bridge Group sold 105,360 Verve Therapeutics shares in Q2 2022, an estimated $2.4M.
  • Ally Bridge Group first reported a position in Verve Therapeutics in Q3 2021 and held it in 3 quarters.
  • Ally Bridge Group's Verve Therapeutics position peaked at $4.07M in Q4 2021.
  • 101 funds tracked by Wall St. Rank held Verve Therapeutics as of Q2 2022.

Based on Ally Bridge Group's 13F filing for Q2 2022, filed 15 Aug 2022.